Gufic BiosciencesBOM:509079 -4.08%80 Pretax Margin % is 11.50% as of Mar. 2026, which is 6% above its 10-year median of 10.90. GuruFocus rates BOM:509079 with a GF Score™ of 80/100 and a GF Value™ of ₹408.23 (Fairly Valued). The stock has 7 warning signs investors should review. Among 956 Drug Manufacturers companies, Gufic Biosciences ranks better than 55.65% on this metric.
The historical rank and industry rank for Gufic Biosciences's Pretax Margin % or its related term are showing as below:
BOM:509079'
s Pretax Margin % Range Over the Past 10 Years
Min: 5.98 Med: 10.9 Max: 17.79
Current: 9.17
BOM:509079's Pretax Margin % is ranked better than 55.65% of 956
companies
in the Drug Manufacturers industry
Industry Median: 7.285
vs BOM:509079: 9.17
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Gufic Biosciences Pretax Margin % Related Terms
Gufic Biosciences Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Gufic Biosciences's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:509079 vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gufic Biosciences's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gufic Biosciences Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gufic Biosciences's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Gufic Biosciences's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gufic Biosciences (BOM:509079) has a Pretax Margin % of 11.50% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Gufic Biosciences and its competitors. This is near median its historical median of 10.90. Over the past decade, Gufic Biosciences' Pretax Margin % has ranged from 5.98 to 17.79. According to the industry distribution chart, Gufic Biosciences ranks #424 out of 956 companies in the Drug Manufacturers industry, placing it in the top 44.4%.
Is Gufic Biosciences' Pretax Margin % too high?
Gufic Biosciences' current Pretax Margin % of 11.50% is near median its 10-year median of 10.90. Over the past 10 years, this metric has ranged from a low of 5.98 to a high of 17.79. The Drug Manufacturers industry median Pretax Margin % is 7.29. Gufic Biosciences' value of 11.50% is 57.9% above this industry median. Based on the distribution chart, Gufic Biosciences ranks #424 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Gufic Biosciences has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gufic Biosciences' Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gufic Biosciences ranks #424 out of 956 companies for Pretax Margin %. This puts Gufic Biosciences in the upper half of its industry. The industry median Pretax Margin % is 7.29. Gufic Biosciences' value of 11.50% is 57.9% above this benchmark. Historically, Gufic Biosciences' own Pretax Margin % has ranged from 5.98 to 17.79 over the past decade. While the company's 10-year median is 10.90 vs. the industry median of 7.29, Gufic Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.29, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gufic Biosciences's current Pretax Margin % of 11.50% is 57.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Gufic Biosciences and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gufic Biosciences's current Pretax Margin % is 11.50%, which is near median its own 10-year median of 10.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gufic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Gufic Biosciences (BOM:509079) is currently considered Fairly Valued. The stock's GF Value™ is ₹408.23, compared to a current price of ₹375.05 — trading 8.1% below its estimated fair value. The current Pretax Margin % is 11.50%, which is near median its 10-year median of 10.90 and 57.9% above the Drug Manufacturers industry median of 7.29. Gufic Biosciences' overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Gufic Biosciences (BOM:509079), the current Pretax Margin % is 11.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gufic Biosciences (BOM:509079) Overvalued in 2026?
Based on GuruFocus' analysis, Gufic Biosciences stock appears to be undervalued.
The current stock price of ₹375.05 is trading 8.1% below its estimated GF Value™ of ₹408.23.
GuruFocus considers Gufic Biosciences to be Fairly Valued.
Key valuation signals for BOM:509079:
Pretax Margin %: 11.50% (near median its 10-year median of 10.90)
GF Value™: ₹408.23 vs. price of ₹375.05 (8.1% below fair value)
Industry Position: 57.9% above the Drug Manufacturers median (#424 of 956)
No single metric tells the full story. See the BOM:509079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare, Criticare Life, Ferticare, Spark, Herbal, and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral, and a proton-pump inhibitor. It derives maximum revenue from India.
80GF Score
Get the complete analysis for BOM:509079
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:509079 has been successfully added to your 
